Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ABT - Abbott Labs -- Ignore unavailable to you. Want to Upgrade?

To: Skywatcher who wrote (271)	6/8/2000 1:29:00 PM
From: Skywatcher	Respond to of 328

Abbott Elects Dr. Jeffrey Leiden Chief Scientific Officer ABBOTT PARK, Ill., June 8 /PRNewswire/ -- Abbott Laboratories today announced that Jeffrey Leiden, M.D., Ph.D. has been elected senior vice president and chief scientific officer by the board of directors of Abbott Laboratories effective July 1, 2000. This is a newly created position reporting to the chief executive officer. ``A commitment to scientific leadership is core to our business,'' said Miles D. White, chairman and chief executive officer Abbott Laboratories. ``Jeff brings an outstanding background in science and medicine and will play a leadership role in guiding our global research and development strategies across all of our diverse health care businesses.'' Dr. Leiden has a distinguished career as a physician, scientist and businessman. He most recently served as the Elkan R. Blout Professor of Biological Sciences, Harvard School of Public Health and Professor of Medicine, Harvard Medical School. Prior to that, he was the Frederick H. Rawson Professor of Medicine and Pathology and Chief of the Section of Cardiology at the University of Chicago. He has served on the editorial boards of numerous medical journals, primarily in the fields of gene therapy molecular medicine and cardiology. His extensive business and consulting experience includes both the pharmaceutical and medical device arenas. He was a founder of Cardiogene, Inc., a biotechnology company specializing in cardiovascular gene therapy. Dr. Leiden has consulted with a number of leading health care corporations including Pfizer, Bristol Meyers-Squibb and Boston Scientific Inc. Dr. Leiden has served on the board of directors of Abbott since 1999 and will retain his seat on the Board. He will serve as chairman of Abbott's Scientific Governing Council. The Scientific Governing Council includes all vice-presidents of Research and Development and is the company's internal scientific forum charged with providing strategic guidance on scientific initiatives. Abbott Laboratories is a global, diversified health care company devoted to the discovery, development, manufacture and marketing of pharmaceutical, diagnostic, nutritional and hospital products. The company employs 57,000 people and markets its products in more than 130 countries. In 1999, the company's sales and net earnings were $13.2 billion and $2.5 billion, respectively, with diluted earnings per share of $1.57.